Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leukemia, Myeloid, Acute × siltuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Cytokine Release Syndrome 4 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Thrombocytosis 1 Thrombocytopenia 1 Schwannomatosis 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pancreatic Neoplasms 1 Pain 1 Neurilemmoma 1 Neoplasms, Plasma Cell 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Large Granular Lymphocytic 1 Immunoglobulin Light-chain Amyloidosis 1 Chronic Pain 1 Anemia 1 Advanced Malignant Solid Neoplasm 1

Interventions

Cytarabine 321 Cyclophosphamide 210 Azacitidine 189 fludarabine phosphate 175 venetoclax 172 fludarabine 167 Busulfan 126 Decitabine 118 Mycophenolic Acid 106 Whole-Body Irradiation 105 Peripheral Blood Stem Cell Transplantation 101 Tacrolimus 93 Filgrastim 92 Idarubicin 90 Granulocyte Colony-Stimulating Factor 86 Cyclosporine 80 Melphalan 79 Methotrexate 72 Etoposide 66 Daunorubicin 66 Antilymphocyte Serum 64 Clofarabine 61 Mitoxantrone 59 Gemtuzumab 55 Stem Cell Transplantation 48 Thiotepa 41 Injections 41 Cladribine 40 thymoglobulin 39 CPX-351 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05697510 2023-04-06

SILTUXILAM

Nantes University Hospital

Phase 1 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡